Management Team

Ophthotech has assembled a team with proven experience in research, clinical development and commercialization of novel therapies for diseases of the eye.

Glenn Sblendorio

Glenn P. Sblendorio, M.B.A.

President and Chief Executive Officer

Glenn Sblendorio, M.B.A., is Chief Executive Officer and President of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the Board of Directors of Ophthotech from 2013 to 2016 and rejoined the Board in May 2017. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.
Todd D.C. Anderman

Todd D.C. Anderman

Vice President, General Counsel & Corporate Secretary

Todd D.C. Anderman is Vice President, General Counsel & Corporate Secretary of Ophthotech. Mr. Anderman joined Ophthotech in 2015 after representing the company since 2012 while practicing corporate law at Wilmer Cutler Pickering Hale and Dorr LLP. While at WilmerHale, Mr. Anderman’s practice focused on representing life sciences and technology companies. Mr. Anderman began his career as a corporate attorney at Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising on merger, acquisition, divestiture, licensing and financing transactions. Mr. Anderman received his B.A. in Government and Philosophy form the College of Arts & Sciences at Cornell University and his J.D. from the University of Pennsylvania Law School.
David J. Carroll

David F. Carroll, M.B.A.

Chief Financial Officer

David Carroll, M.B.A, is the Chief Financial Officer of Ophthotech Corporation. Mr. Carroll joined Ophthotech in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb.

Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Evelyn Harrison

Evelyn Harrison, M.B.A.

Chief Clinical Operations Officer

Evelyn Harrison, M.B.A., is the Chief Clinical Operations Officer of Ophthotech Corporation. She brings more than 23 years of management and clinical research experience.

Prior to joining Ophthotech, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison, played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.

Kourous A. Rezaei, M.D.

Kourous A. Rezaei, M.D.

Senior Vice President and Chief Medical Officer

Dr. Rezaei serves as the Senior Vice President and Chief Medical Officer of Ophthotech Corporation. He is a board certified ophthalmologist who specializes in the medical and surgical treatment of vitreoretinal diseases, and has been recognized with multiple awards in ophthalmology, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. Dr. Rezaei had served on the Editorial Board of the journal of Investigative Ophthalmology & Visual Science (IOVS) and currently is a voting member on the Board of Directors of the American Society of Retina Specialists (ASRS). He has authored over 30 articles, five medical textbook chapters, and has presented over 80 abstracts in 26 countries. Dr. Rezaei is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a senior partner at Illinois Retina Associates in Chicago. Previously, he was the Director of Vitreoretinal Service at the University of Chicago. Dr. Rezaei also founded “ChannelR”, a digital media education program for retina specialists.

Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.

Keith Westby

Keith Westby, M.B.A.

Senior Vice President and Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of Ophthotech Corporation. Mr. Westby joined Ophthotech in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations of Ophthotech. Prior to joining Ophthotech, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a Bachelor of Science degree in Applied Physics from the State University of New York, College at Geneseo, a Master of Science degree in Engineering Management from Drexel University, and a Master of Business Administration degree from Columbia Business School.

Amy Sheehan

Senior Vice President and Chief Human Resources Officer

Amy Sheehan is the Senior Vice President & Chief Human Resources Officer at Ophthotech. Ms. Sheehan joined Ophthotech in 2014 and brings over 20 years of human resources experience in the biotechnology and manufacturing industries. Prior to joining Ophthotech Ms. Sheehan led Human Resources for the Electronic Systems Division of Parker Hannifin, a publicly traded Fortune 250 global company. Earlier in Ms. Sheehan’s career she held leadership positions of increasing responsibility in human resources at OSI Pharmaceuticals, a publicly traded biotechnology company. Throughout Ms. Sheehan’s career she oversaw Human Resources teams and led successful HR strategies in talent acquisition, culture, total rewards, leadership development and training. She holds a Master’s degree in Human Resources Management and a Bachelor’s degree in psychology from Hofstra University.